Sanofi-aventis and Novozymes Announce Antibiotic Development and Commercialization Collaboration
News Dec 26, 2008
Sanofi-aventis announced the signature of a global licensing and collaboration agreement with Novozymes for the development and marketing of a potential new antibiotic.
The drug candidate is an antimicrobial peptide named Plectasin NZ2114 that targets the treatment of severe infections, such as pneumonia and septicaemia, caused by bacteria like Staphylococcus and Streptococcus.
Under the terms of the agreement Sanofi-aventis has been granted an exclusive worldwide license for the development, registration and commercialization of the drug. The two companies will jointly work to develop and implement commercial-scale manufacturing of the Plectasin NZ2114 drug substance, with the goal of introducing a recombinant process building on Novozymes' proprietary expression technology.
"Plectasin NZ2114 is the first drug candidate that Novozymes has outlicensed for further preclinical and clinical development. Teaming up with one of the largest pharmaceutical companies in the world is the type of collaborations we were looking for," said Per Falholt, Executive Vice President, Research & Development, Novozymes.
"The innovative mechanism of action of Plectasin NZ2114 makes it potentially active against bacteria resistant to currently available treatments. We are looking forward to developing Plectasin NZ2114 for the treatment of severe infections such as pneumonia, septicaemia, and complicated skin and soft tissue infections," declared Dr. Marc Cluzel, Senior Vice President, Research & Development, sanofi-aventis.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
May 21 - May 22, 2018